Physician profile
Paul H Smith
NPI 1770585176
$684.94
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.16 · 2022: $230 · 2023: $280 · 2024: $79.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.11 | 2022-2023 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $75.54 | 2022-2024 | Mounjaro |
| Novo Nordisk INC | $58.73 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $48.79 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.41 | 2023-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $44.26 | 2022 | |
| Pfizer INC. | $44.23 | 2019-2022 | |
| Bausch Health US, LLC | $39.60 | 2023-2024 | Aplenzin |
| Amarin Pharma, INC. | $38.82 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.63 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $20.65 | 2019 | |
| Itamar Medical INC | $18.31 | 2023 | Watchpatone |
| Ermi LLC | $13.81 | 2019 | |
| Glaxosmithkline, LLC. | $13.62 | 2019 | |
| Lundbeck LLC | $13.21 | 2023 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.95 | 2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.